Phytochemicals targeting estrogen receptors: Beneficial rather than adverse effects?

International Journal of Molecular Sciences

Volumn 18, Issue 7, 2017, Pages

  Lecomte, Sylvain ^a   Demay, Florence ^a   Ferrière, François ^a   Pakdel, Farzad ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Cancer; Cell signaling; Epigenetic regulation; Estrogen receptor; Ligand; Selective estrogen receptor modulators; Transcription; Xenoestrogens

Indexed keywords

APIGENIN; COUMESTAN; COUMESTROL; DAIDZEIN; DICKKOPF 1 PROTEIN; DNA METHYLTRANSFERASE; ENTERODIOL; ENTEROLACTONE; EPIDERMAL GROWTH FACTOR; EQUOL; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; GLYCEOLLIN; GLYCEOLLIN I; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIQUIRITIGENIN; MATAIRESINOL; PHYTOALEXIN; PHYTOESTROGEN; PLANT MEDICINAL PRODUCT; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE; PROTEIN KINASE B; RESVERATROL; SECOISOLARICIRESINOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZEARALENONE; ANTIESTROGEN; PHYTOCHEMICAL;

BINDING AFFINITY; CANCER INHIBITION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CLINICAL TRIAL (TOPIC); CPG ISLAND; ENZYME ACTIVITY; GENOTOXICITY; HUMAN; METABOLITE; NONHUMAN; OXIDATIVE STRESS; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; EPIGENESIS, GENETIC; ESTROGEN ANTAGONISTS; HUMANS; PHYTOCHEMICALS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 85021624644     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18071381     Document Type: Review

References (137)

1. Couse, J.F.; Korach, K.S. Estrogen receptor null mice: What have we learned and where will they lead us? Endocr. Rev. 1999, 20, 358–417.
2. Gustafsson, J.-A. What pharmacologists can learn from recent advances in estrogen signaling. Trends Pharmacol. Sci. 2003, 24, 479–485.
3. Germain, P.; Staels, B.; Dacquet, C.; Spedding, M.; Laudet, V. Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 2006, 58, 685–704.
4. Safe, S.; Kim, K.; Kim, K. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J. Mol. Endocrinol. 2008, 41, 263–275.
5. Carroll, J.S.; Meyer, C.A.; Song, J.; Li, W.; Geistlinger, T.R.; Eeckhoute, J.; Brodsky, A.S.; Keeton, E.K.; Fertuck, K.C.; Hall, G.F.; et al. Genome-wide analysis of estrogen receptor 2006, 38, 1289–1297.
6. Le Dily, F.; Beato, M. TADs as modular and dynamic units for gene regulation by hormones. FEBS Lett. 2015, 589, 2885–2892. [CrossRef] [PubMed]
7. Le Dily, F.; Baù, D.; Pohl, A.; Vicent, G.P.; Serra, F.; Soronellas, D.; Castellano, G.; Wright, R.H.G.; Ballare, C.; Filion, G.; et al. Distinct structural transitions of chromatin topological domains correlate with coordinated hormone-induced gene regulation. Genes Dev. 2014, 28, 2151–2162. [CrossRef] [PubMed]
8. Nilsson, S.; Mäkelä, S.; Treuter, E.; Tujague, M.; Thomsen, J.; Andersson, G.; Enmark, E.; Pettersson, K.; Warner, M.; Gustafsson, J.A. Mechanisms of estrogen action. Physiol. Rev. 2001, 81, 1535–1565. [PubMed]
9. La Rosa, P.; Pesiri, V.; Leclercq, G.; Marino, M.; Acconcia, F. Palmitoylation regulates 17β-estradiol-induced estrogen receptor-α degradation and transcriptional activity. Mol. Endocrinol. 2012, 26, 762–774. [CrossRef] [PubMed]
10. Pedram, A.; Razandi, M.; Aitkenhead, M.; Hughes, C.C.W.; Levin, E.R. Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J. Biol. Chem. 2002, 277, 50768–50775. [CrossRef] [PubMed]
11. Vicent, G.P.; Nacht, A.S.; Zaurín, R.; Ballaré, C.; Clausell, J.; Beato, M. Minireview: Role of kinases and chromatin remodeling in progesterone signaling to chromatin. Mol. Endocrinol. 2010, 24, 2088–2098. [CrossRef] [PubMed]
12. Levin, E.R. Extranuclear estrogen receptor’s roles in physiology: Lessons from mouse models. Am. J. Physiol. Endocrinol. Metab. 2014, 307, E133–E140. [CrossRef] [PubMed]
13. Gosden, J.R.; Middleton, P.G.; Rout, D. Localization of the human oestrogen receptor gene to chromosome 6q24—-q27 by in situ hybridization. Cytogenet. Cell Genet. 1986, 43, 218–220. [CrossRef] [PubMed]
14. Enmark, E.; Pelto-Huikko, M.; Grandien, K.; Lagercrantz, S.; Lagercrantz, J.; Fried, G.; Nordenskjöld, M.; Gustafsson, J.A. Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J. Clin. Endocrinol. Metab. 1997, 82, 4258–4265. [CrossRef] [PubMed]
15. Kerdivel, G.; Flouriot, G.; Pakdel, F. Modulation of estrogen receptor α activity and expression during breast cancer progression. Vitam. Horm. 2013, 93, 135–160. [PubMed]
16. Wang, Z.; Zhang, X.; Shen, P.; Loggie, B.W.; Chang, Y.; Deuel, T.F. Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66. Biochem. Biophys. Res. Commun. 2005, 336, 1023–1027. [CrossRef] [PubMed]
17. Saunders, P.T. Oestrogen receptor β (ER β). Rev. Reprod. 1998, 3, 164–171. [CrossRef] [PubMed]
18. Delbès, G.; Levacher, C.; Duquenne, C.; Racine, C.; Pakarinen, P.; Habert, R. Endogenous estrogens inhibit mouse fetal Leydig cell development via estrogen receptor α. Endocrinology 2005, 146, 2454–2461. [CrossRef] [PubMed]
19. Staub, C.; Rauch, M.; Ferrière, F.; Trépos, M.; Dorval-Coiffec, I.; Saunders, P.T.; Cobellis, G.; Flouriot, G.; Saligaut, C.; Jégou, B. Expression of Estrogen Receptor ESR1 and Its 46-kDa Variant in the Gubernaculum Testis. Biol. Reprod. 2005, 73, 703–712. [CrossRef] [PubMed]
20. Wilson, M.E.; Westberry, J.M.; Trout, A.L. Estrogen receptor-α gene expression in the cortex: Sex differences during development and in adulthood. Horm. Behav. 2011, 59, 353–357. [CrossRef] [PubMed]
21. Fan, X.; Kim, H.-J.; Warner, M.; Gustafsson, J.-A. Estrogen receptor β is essential for sprouting of nociceptive primary afferents and for morphogenesis and maintenance of the dorsal horn interneurons. Proc. Natl. Acad. Sci. USA 2007, 104, 13696–13701. [CrossRef] [PubMed]
22. Kerdivel, G.; Habauzit, D.; Pakdel, F. Assessment and molecular actions of endocrine-disrupting chemicals that interfere with estrogen receptor pathways. Int. J. Endocrinol. 2013, 2013, 501851. [CrossRef] [PubMed]
23. Sohoni, P.; Sumpter, J.P. Several environmental oestrogens are also anti-androgens. J. Endocrinol. 1998, 158, 327–339. [CrossRef] [PubMed]
24. Sonnenschein, C.; Soto, A.M. An updated review of environmental estrogen and androgen mimics and antagonists. J. Steroid Biochem. Mol. Biol. 1998, 65, 143–150. [CrossRef]
25. Rasier, G.; Toppari, J.; Parent, A.-S.; Bourguignon, J.-P. Female sexual maturation and reproduction after prepubertal exposure to estrogens and endocrine disrupting chemicals: A review of rodent and human data. Mol. Cell. Endocrinol. 2006, 254–255, 187–201. [CrossRef] [PubMed]
26. Toppari, J.; Virtanen, H.; Skakkebaek, N.E.; Main, K.M. Environmental effects on hormonal regulation of testicular descent. J. Steroid Biochem. Mol. Biol. 2006, 102, 184–186. [CrossRef] [PubMed]
27. Barouki, R.; Coumoul, X.; Fernandez-Salguero, P.M. The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett. 2007, 581, 3608–3615. [CrossRef] [PubMed]
28. Liu, Z.; Kanjo, Y.; Mizutani, S. A review of phytoestrogens: Their occurrence and fate in the environment. Water Res. 2010, 44, 567–577. [CrossRef] [PubMed]
29. Fantini, M.; Benvenuto, M.; Masuelli, L.; Frajese, G.; Tresoldi, I.; Modesti, A.; Bei, R. In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphenols and anticancer drugs: Perspectives on cancer treatment. Int. J. Mol. Sci. 2015, 16, 9236–9282. [CrossRef] [PubMed]
30. Shukla, S.; Gupta, S. Apigenin: A promising molecule for cancer prevention. Pharm. Res. 2010, 27, 962–978. [CrossRef] [PubMed]
31. Marzocchella, L.; Fantini, M.; Benvenuto, M.; Masuelli, L.; Tresoldi, I.; Modesti, A.; Bei, R. Dietary flavonoids: Molecular mechanisms of action as anti-inflammatory agents. Recent Pat. Inflamm. Allergy Drug Discov. 2011, 5, 200–220. [CrossRef] [PubMed]
32. Beecher, G.R. Overview of dietary flavonoids: Nomenclature, occurrence and intake. J. Nutr. 2003, 133, 3248S–3254S. [PubMed]
33. Setchell, K.D.R.; Clerici, C. Equol: History, chemistry, and formation. J. Nutr. 2010, 140, 1355S–1362S. [CrossRef] [PubMed]
34. National Library of Medecine-MeSH National Library of Medecine-MeSH, 2016. Available online: https://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi (accessed on 12 November 2016).
35. Van de Schans, M.G. M.; Vincken, J.-P.; Bovee, T.F. H.; Cervantes, A.D.; Logtenberg, M.J.; Gruppen, H. Structural changes of 6a-hydroxy-pterocarpans upon heating modulate their estrogenicity. J. Agric. Food Chem. 2014, 62, 10475–10484. [CrossRef] [PubMed]
36. Zimmermann, M.C.; Tilghman, S.L.; Boué, S.M.; Salvo, V.A.; Elliott, S.; Williams, K.Y.; Skripnikova, E.V.; Ashe, H.; Payton-Stewart, F.; Vanhoy-Rhodes, L.; et al. Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy. J. Pharmacol. Exp. Ther. 2010, 332, 35–45. [CrossRef] [PubMed]
37. Ayers, A.R.; Ebel, J.; Finelli, F.; Berger, N.; Albersheim, P. Host-pathogen interactions: IX. Quantitative assays of elicitor activity and characterization of the elicitor present in the extracellular medium of cultures of Phytophthora megasperma var. sojae. Plant Physiol. 1976, 57, 751–759. [CrossRef] [PubMed]
38. Nikov, G.N.; Hopkins, N.E.; Boue, S.; Alworth, W.L. Interactions of dietary estrogens with human estrogen receptors and the effect on estrogen receptor-estrogen response element complex formation. Environ. Health Perspect. 2000, 108, 867–872. [CrossRef] [PubMed]
39. Tuskaev, V.A. Synthesis and biological activity of coumestan derivatives. Pharm. Chem. J. 2013, 47, 1–11. [CrossRef]
40. Nehybová, T.; Šmarda, J.; Beneš, P. Plant coumestans: Recent advances and future perspectives in cancer therapy. Anticancer Agents Med. Chem. 2014, 14, 1351–1362. [CrossRef] [PubMed]
41. Bickoff, E.M.; Booth, A.N.; Lyman, R.L.; Livingston, A.L.; Thompson, C.R.; Deeds, F. Coumestrol, a new estrogen isolated from forage crops. Science 1957, 126, 969–970. [CrossRef] [PubMed]
42. Kuiper, G.G.; Lemmen, J.G.; Carlsson, B.; Corton, J.C.; Safe, S.H.; van der Saag, P.T.; van der Burg, B.; Gustafsson, J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 1998, 139, 4252–4263. [CrossRef] [PubMed]
43. Stervbo, U.; Vang, O.; Bonnesen, C. A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chem. 2007, 101, 449–457. [CrossRef]
44. Gehm, B.D.; McAndrews, J.M.; Chien, P.Y.; Jameson, J.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA 1997, 94, 14138–14143. [CrossRef] [PubMed]
45. Le Corre, L.; Chalabi, N.; Delort, L.; Bignon, Y.-J.; Bernard-Gallon, D.J. Resveratrol and breast cancer chemoprevention: Molecular mechanisms. Mol. Nutr. Food Res. 2005, 49, 462–471. [CrossRef] [PubMed]
46. Rosmalena, A.; Prasasty, V.D.; Hanafi, M.; Budianto, E.; Elya, B. Lignan derivatives potential as Plasmodium falciparum lactate dehydrogenase inhibitors: Molecular docking approach of antiplasmodial drug design. Int. J. Pharm. Pharm. Sci. 2015, 7, 394–398.
47. Mueller, S.O.; Simon, S.; Chae, K.; Metzler, M.; Korach, K.S. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor α (ERα) and ERβ in human cells. Toxicol. Sci. 2004, 80, 14–25. [CrossRef] [PubMed]
48. Shier, W.T.; Shier, A.C.; Xie, W.; Mirocha, C.J. Structure-activity relationships for human estrogenic activity in zearalenone mycotoxins. Toxicon 2001, 39, 1435–1438. [CrossRef]
49. EFSA Panel on Contaminants in the Food Chain Scientific. Opinion on the risks for public health related to the presence of zearalenone in food. EFSA J. 2011, 9, 2197.
50. Lin, P.; Chen, F.; Sun, J.; Zhou, J.; Wang, X.; Wang, N.; Li, X.; Zhang, Z.; Wang, A.; Jin, Y. Mycotoxin zearalenone induces apoptosis in mouse Leydig cells via an endoplasmic reticulum stress-dependent signalling pathway. Reprod. Toxicol. 2015, 52, 71–77. [CrossRef] [PubMed]
51. Le Guevel, R.; Pakdel, F. Assessment of oestrogenic potency of chemicals used as growth promoter by in vitro methods. Hum. Reprod. 2001, 16, 1030–1036. [CrossRef] [PubMed]
52. Frasor, J.; Danes, J.M.; Komm, B.; Chang, K.C.N.; Lyttle, C.R.; Katzenellenbogen, B.S. Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003, 144, 4562–4574. [CrossRef] [PubMed]
53. Chang, E.C.; Frasor, J.; Komm, B.; Katzenellenbogen, B.S. Impact of estrogen receptor β on gene networks regulated by estrogen receptor α in breast cancer cells. Endocrinology 2006, 147, 4831–4842. [CrossRef] [PubMed]
54. Chang, E.C.; Charn, T.H.; Park, S.-H.; Helferich, W.G.; Komm, B.; Katzenellenbogen, J.A.; Katzenellenbogen, B.S. Estrogen Receptors α and β as Determinants of Gene Expression: Influence of Ligand, Dose, and Chromatin Binding. Mol. Endocrinol. 2008, 22, 1032–1043. [CrossRef] [PubMed]
55. Zhao, L.; Mao, Z.; Brinton, R.D. A select combination of clinically relevant phytoestrogens enhances estrogen receptor β-binding selectivity and neuroprotective activities in vitro and in vivo. Endocrinology 2009, 150, 770–783. [CrossRef] [PubMed]
56. Shanle, E.K.; Hawse, J.R.; Xu, W. Generation of stable reporter breast cancer cell lines for the identification of ER subtype selective ligands. Biochem. Pharmacol. 2011, 82, 1940–1949. [CrossRef] [PubMed]
57. Jiang, Y.; Gong, P.; Madak-Erdogan, Z.; Martin, T.; Jeyakumar, M.; Carlson, K.; Khan, I.; Smillie, T.J.; Chittiboyina, A.G.; Rotte, S.C.K.; et al. Mechanisms enforcing the estrogen receptor β selectivity of botanical estrogens. FASEB J. 2013, 27, 4406–4418. [CrossRef] [PubMed]
58. Pons, D.G.; Nadal-Serrano, M.; Blanquer-Rossello, M.M.; Sastre-Serra, J.; Oliver, J.; Roca, P. Genistein Modulates Proliferation and Mitochondrial Functionality in Breast Cancer Cells Depending on ERα/ERβ Ratio. J. Cell. Biochem. 2014, 115, 949–958. [CrossRef] [PubMed]
59. Sotoca, A.M.; Ratman, D.; van der Saag, P.; Ström, A.; Gustafsson, J.A.; Vervoort, J.; Rietjens, I.M.C.M.; Murk, A.J. Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERα/ERβ ratio. J. Steroid Biochem. Mol. Biol. 2008, 112, 171–178. [CrossRef] [PubMed]
60. Russo, M.; Russo, G.L.; Daglia, M.; Kasi, P.D.; Ravi, S.; Nabavi, S.F.; Nabavi, S.M. Understanding genistein in cancer: The good and the bad effects: A review. Food Chem. 2016, 196, 589–600. [CrossRef] [PubMed]
61. Kuo, S.M. Antiproliferative potency of structurally distinct dietary flavonoids on human colon cancer cells. Cancer Lett. 1996, 110, 41–48. [CrossRef]
62. Hwang, K.-A.; Park, M.-A.; Kang, N.-H.; Yi, B.-R.; Hyun, S.-H.; Jeung, E.-B.; Choi, K.-C. Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways. Toxicol. Appl. Pharmacol. 2013, 272, 637–646. [CrossRef] [PubMed]
63. Prietsch, R.F.; Monte, L.G.; da Silva, F.A.; Beira, F.T.; Del Pino, F.A.B.; Campos, V.F.; Collares, T.; Pinto, L.S.; Spanevello, R.M.; Gamaro, G.D.; et al. Genistein induces apoptosis and autophagy in human breast MCF-7 cells by modulating the expression of proapoptotic factors and oxidative stress enzymes. Mol. Cell. Biochem. 2014, 390, 235–242. [CrossRef] [PubMed]
64. Li, Y.; Sarkar, F.H. Inhibition of nuclear factor κB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin. Cancer Res. 2002, 8, 2369–2377. [PubMed]
65. Gong, L.; Li, Y.; Nedeljkovic-Kurepa, A.; Sarkar, F.H. Inactivation of NF-κB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 2003, 22, 4702–4709. [CrossRef] [PubMed]
66. Li, Y.; Meeran, S.M.; Patel, S.N.; Chen, H.; Hardy, T.M.; Tollefsbol, T.O. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer. Mol. Cancer 2013, 12, 9. [CrossRef] [PubMed]
67. Suzuki, R.; Kang, Y.; Li, X.; Roife, D.; Zhang, R.; Fleming, J.B. Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells. Anticancer Res. 2014, 34, 4685–4692. [PubMed]
68. Li, C.; Teng, R.-H.; Tsai, Y.-C.; Ke, H.-S.; Huang, J.-Y.; Chen, C.-C.; Kao, Y.-L.; Kuo, C.-C.; Bell, W.R.; Shieh, B. H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells. Br. J. Cancer 2005, 92, 80–88. [CrossRef] [PubMed]
69. Sarkar, F.H.; Li, Y.; Wang, Z.; Padhye, S. Lesson learned from nature for the development of novel anti-cancer agents: Implication of isoflavone, curcumin, and their synthetic analogs. Curr. Pharm. Des. 2010, 16, 1801–1812. [CrossRef] [PubMed]
70. Jagadeesh, S.; Kyo, S.; Banerjee, P.P. Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells. Cancer Res. 2006, 66, 2107–2115. [CrossRef] [PubMed]
71. Wong, C.J.; Casper, R.F.; Rogers, I.M. Epigenetic changes to human umbilical cord blood cells cultured with three proteins indicate partial reprogramming to a pluripotent state. Exp. Cell Res. 2010, 316, 927–939. [CrossRef] [PubMed]
72. Zhang, Y.; Chen, H. Genistein attenuates WNT signaling by up-regulating sFRP2 in a human colon cancer cell line. Exp. Biol. Med. 2011, 236, 714–722. [CrossRef] [PubMed]
73. Gregorieff, A.; Clevers, H. Wnt signaling in the intestinal epithelium: From endoderm to cancer. Genes Dev. 2005, 19, 877–890. [CrossRef] [PubMed]
74. MacDonald, B.T.; Tamai, K.; He, X. Wnt/β-catenin signaling: Components, mechanisms, and diseases. Dev. Cell 2009, 17, 9–26. [CrossRef] [PubMed]
75. Qi, J.; Zhu, Y.-Q.; Luo, J.; Tao, W.-H. Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J. Gastroenterol. 2006, 12, 7113–7117. [CrossRef] [PubMed]
76. Wang, H.; Li, Q.; Chen, H. Genistein affects histone modifications on Dickkopf-related protein 1 (DKK1) gene in SW480 human colon cancer cell line. PLoS ONE 2012, 7, e40955. [CrossRef] [PubMed]
77. Rawson, J.B.; Manno, M.; Mrkonjic, M.; Daftary, D.; Dicks, E.; Buchanan, D.D.; Younghusband, H.B.; Parfrey, P.S.; Young, J.P.; Pollett, A.; et al. Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. Carcinogenesis 2011, 32, 741–747. [CrossRef] [PubMed]
78. Aguilera, O.; Fraga, M.F.; Ballestar, E.; Paz, M.F.; Herranz, M.; Espada, J.; García, J.M.; Muñoz, A.; Esteller, M.; González-Sancho, J.M. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 2006, 25, 4116–4121. [CrossRef] [PubMed]
79. Hirata, H.; Hinoda, Y.; Nakajima, K.; Kawamoto, K.; Kikuno, N.; Ueno, K.; Yamamura, S.; Zaman, M.S.; Khatri, G.; Chen, Y.; et al. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int. J. Cancer 2011, 128, 1793–1803. [CrossRef] [PubMed]
80. Ravindranath, M.H.; Muthugounder, S.; Presser, N.; Viswanathan, S. Anticancer therapeutic potential of soy isoflavone, genistein. Adv. Exp. Med. Biol. 2004, 546, 121–165. [PubMed]
81. Mahmoud, A.M.; Al-Alem, U.; Ali, M.M.; Bosland, M.C. Genistein increases estrogen receptor β expression in prostate cancer via reducing its promoter methylation. J. Steroid Biochem. Mol. Biol. 2015, 152, 62–75. [CrossRef] [PubMed]
82. Anastasius, N.; Boston, S.; Lacey, M.; Storing, N.; Whitehead, S.A. Evidence that low-dose, long-term genistein treatment inhibits oestradiol-stimulated growth in MCF-7 cells by down-regulation of the PI3-kinase/Akt signalling pathway. J. Steroid Biochem. Mol. Biol. 2009, 116, 50–55. [CrossRef] [PubMed]
83. Jawaid, K.; Crane, S.R.; Nowers, J.L.; Lacey, M.; Whitehead, S.A. Long-term genistein treatment of MCF-7 cells decreases acetylated histone 3 expression and alters growth responses to mitogens and histone deacetylase inhibitors. J. Steroid Biochem. Mol. Biol. 2010, 120, 164–171. [CrossRef] [PubMed]
84. Whitten, P.L.; Patisaul, H.B. Cross-species and interassay comparisons of phytoestrogen action. Environ. Health Perspect. 2001. [CrossRef]
85. Soukup, S.T.; Al-Maharik, N.; Botting, N.; Kulling, S.E. Quantification of soy isoflavones and their conjugative metabolites in plasma and urine: An automated and validated UHPLC-MS/MS method for use in large-scale studies. Anal. Bioanal. Chem. 2014, 406, 6007–6020. [CrossRef] [PubMed]
86. Lee, S.-A.; Shu, X.-O.; Li, H.; Yang, G.; Cai, H.; Wen, W.; Ji, B.-T.; Gao, J.; Gao, Y.-T.; Zheng, W. Adolescent and adult soy food intake and breast cancer risk: Results from the shanghai women’s health study. Am. J. Clin. Nutr. 2009, 89, 1920–1926. [CrossRef] [PubMed]
87. Barnes, S. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res. Treat. 1997, 46, 169–179. [CrossRef] [PubMed]
88. Adlercreutz, H. Lignans and human health. Crit. Rev. Clin. Lab. Sci. 2007, 44, 483–525. [CrossRef] [PubMed]
89. Hamilton-Reeves, J.M.; Rebello, S.A.; Thomas, W.; Slaton, J.W.; Kurzer, M.S. Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-β expression or serum hormonal profiles in men at high risk of prostate cancer. J. Nutr. 2007, 137, 1769–1775. [PubMed]
90. Pendleton, J.M.; Tan, W.W.; Anai, S.; Chang, M.; Hou, W.; Shiverick, K.T.; Rosser, C.J. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 2008, 8, 132. [CrossRef] [PubMed]
91. Goetzl, M.A.; Van Veldhuizen, P.J.; Thrasher, J.B. Effects of soy phytoestrogens on the prostate. Prostate Cancer Prostatic Dis. 2007, 10, 216–223. [CrossRef] [PubMed]
92. Adams, K.F.; Chen, C.; Newton, K.M.; Potter, J.D.; Lampe, J.W. Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial. Cancer Epidemiol. Biomark. Prev. 2004, 13, 644–648.
93. Mahmoud, A.M.; Yang, W.; Bosland, M.C. Soy isoflavones and prostate cancer: A review of molecular mechanisms. J. Steroid Biochem. Mol. Biol. 2014, 140, 116–132. [CrossRef] [PubMed]
94. Munro, I.C.; Harwood, M.; Hlywka, J.J.; Stephen, A.M.; Doull, J.; Flamm, W.G.; Adlercreutz, H. Soy isoflavones: A safety review. Nutr. Rev. 2003, 61, 1–33. [CrossRef] [PubMed]
95. He, F.-J.; Chen, J.-Q. Consumption of soybean, soy foods, soy isoflavones and breast cancer incidence: Differences between Chinese women and women in Western countries and possible mechanisms. Food Sci. Hum. Wellness 2013, 2, 146–161. [CrossRef]
96. Ju, Y.H.; Carlson, K.E.; Sun, J.; Pathak, D.; Katzenellenbogen, B.S.; Katzenellenbogen, J.A.; Helferich, W.G. Estrogenic effects of extracts from cabbage, fermented cabbage, and acidified brussels sprouts on growth and gene expression of estrogen-dependent human breast cancer (MCF-7) cells. J. Agric. Food Chem. 2000, 48, 4628–4634. [CrossRef] [PubMed]
97. Breinholt, V.; Hossaini, A.; Svendsen, G.W.; Brouwer, C.; Nielsen, E. Estrogenic activity of flavonoids in mice. The importance of estrogen receptor distribution, metabolism and bioavailability. Food Chem. Toxicol. 2000, 38, 555–564. [CrossRef]
98. Owens, W.; Ashby, J.; Odum, J.; Onyon, L. The OECD program to validate the rat uterotrophic bioassay. Phase 2: Dietary phytoestrogen analyses. Environ. Health Perspect. 2003, 111, 1559–1567. [CrossRef] [PubMed]
99. Phrakonkham, P.; Chevalier, J.; Desmetz, C.; Pinnert, M.-F.; Bergès, R.; Jover, E.; Davicco, M.-J.; Bennetau-Pelissero, C.; Coxam, V.; Artur, Y.; et al. Isoflavonoid-based bone-sparing treatments exert a low activity on reproductive organs and on hepatic metabolism of estradiol in ovariectomized rats. Toxicol. Appl. Pharmacol. 2007, 224, 105–115. [CrossRef] [PubMed]
100. Cederroth, C.R.; Zimmermann, C.; Nef, S. Soy, phytoestrogens and their impact on reproductive health. Mol. Cell. Endocrinol. 2012, 355, 192–200. [CrossRef] [PubMed]
101. Jefferson, W.N.; Padilla-Banks, E.; Clark, G.; Newbold, R.R. Assessing estrogenic activity of phytochemicals using transcriptional activation and immature mouse uterotrophic responses. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2002, 777, 179–189. [CrossRef]
102. Inudo, M.; Ishibashi, H.; Matsumura, N.; Matsuoka, M.; Mori, T.; Taniyama, S.; Kadokami, K.; Koga, M.; Shinohara, R.; Hutchinson, T.H.; et al. Effect of estrogenic activity, and phytoestrogen and organochlorine pesticide contents in an experimental fish diet on reproduction and hepatic vitellogenin production in medaka (Oryzias latipes). Comp. Med. 2004, 54, 673–680. [PubMed]
103. Kobayashi, M.; Ishibashi, H.; Moriwaki, T.; Koshiishi, T.; Ogawa, S.; Matsumoto, T.; Arizono, K.; Watabe, S. Production of low-estrogen goldfish diet for in vivo endocrine disrupter test. Environ. Sci. 2006, 13, 125–136. [PubMed]
104. Bagheri, T.; Imanpoor, M.R.; Jafari, V.; Bennetau-Pelissero, C. Reproductive impairment and endocrine disruption in goldfish by feeding diets containing soybean meal. Anim. Reprod. Sci. 2013, 139, 136–144. [CrossRef] [PubMed]
105. Tan, K.A. L.; Walker, M.; Morris, K.; Greig, I.; Mason, J.I.; Sharpe, R.M. Infant feeding with soy formula milk: Effects on puberty progression, reproductive function and testicular cell numbers in marmoset monkeys in adulthood. Hum. Reprod. 2006, 21, 896–904. [CrossRef] [PubMed]
106. Adachi, T.; Ono, Y.; Koh, K.B.; Takashima, K.; Tainaka, H.; Matsuno, Y.; Nakagawa, S.; Todaka, E.; Sakurai, K.; Fukata, H.; et al. Long-term alteration of gene expression without morphological change in testis after neonatal exposure to genistein in mice: Toxicogenomic analysis using cDNA microarray. Food Chem. Toxicol. 2004, 42, 445–452. [CrossRef] [PubMed]
107. Persky, R.W.; Turtzo, L.C.; McCullough, L.D. Stroke in women: Disparities and outcomes. Curr. Cardiol. Rep. 2010, 12, 6–13. [CrossRef] [PubMed]
108. Wuttke, W.; Jarry, H.; Westphalen, S.; Christoffel, V.; Seidlová-Wuttke, D. Phytoestrogens for hormone replacement therapy? J. Steroid Biochem. Mol. Biol. 2002, 83, 133–147. [CrossRef]
109. Sehmisch, S.; Uffenorde, J.; Maehlmeyer, S.; Tezval, M.; Jarry, H.; Stuermer, K.M.; Stuermer, E.K. Evaluation of bone quality and quantity in osteoporotic mice–the effects of genistein and equol. Phytomedicine 2010, 17, 424–430. [CrossRef] [PubMed]
110. Raghu Nadhanan, R.; Skinner, J.; Chung, R.; Su, Y.-W.; Howe, P.R.; Xian, C.J. Supplementation with fish oil and genistein, individually or in combination, protects bone against the adverse effects of methotrexate chemotherapy in rats. PLoS ONE 2013, 8, e71592. [CrossRef] [PubMed]
111. Canal Castro, C.; Pagnussat, A.S.; Orlandi, L.; Worm, P.; Moura, N.; Etgen, A.M.; Alexandre Netto, C. Coumestrol has neuroprotective effects before and after global cerebral ischemia in female rats. Brain Res. 2012, 1474, 82–90. [CrossRef] [PubMed]
112. Anway, M.D.; Leathers, C.; Skinner, M.K. Endocrine disruptor vinclozolin induced epigenetic transgenerational adult-onset disease. Endocrinology 2006, 147, 5515–5523. [CrossRef] [PubMed]
113. Jirtle, R.L.; Skinner, M.K. Environmental epigenomics and disease susceptibility. Nat. Rev. Genet. 2007, 8, 253–262. [CrossRef] [PubMed]
114. Salian, S.; Doshi, T.; Vanage, G. Impairment in protein expression profile of testicular steroid receptor coregulators in male rat offspring perinatally exposed to Bisphenol A. Life Sci. 2009, 85, 11–18. [CrossRef] [PubMed]
115. Guerrero-Bosagna, C.M.; Skinner, M.K. Environmental epigenetics and phytoestrogen/phytochemical exposures. J. Steroid Biochem. Mol. Biol. 2014, 139, 270–276. [CrossRef] [PubMed]
116. Bruner-Tran, K.L.; Osteen, K.G. Developmental exposure to TCDD reduces fertility and negatively affects pregnancy outcomes across multiple generations. Reprod. Toxicol. 2011, 31, 344–350. [CrossRef] [PubMed]
117. Manikkam, M.; Tracey, R.; Guerrero-Bosagna, C.; Skinner, M.K. Dioxin (TCDD) induces epigenetic transgenerational inheritance of adult onset disease and sperm epimutations. PLoS ONE 2012, 7, e46249. [CrossRef] [PubMed]
118. Hao, C.; Gely-Pernot, A.; Kervarrec, C.; Boudjema, M.; Becker, E.; Khil, P.; Tevosian, S.; Jégou, B.; Smagulova, F. Exposure to the widely used herbicide atrazine results in deregulation of global tissue-specific RNA transcription in the third generation and is associated with a global decrease of histone trimethylation in mice. Nucleic Acids Res. 2016. [CrossRef] [PubMed]
119. Sondergaard, T.E.; Hansen, F.T.; Purup, S.; Nielsen, A.K.; Bonefeld-Jørgensen, E.C.; Giese, H.; Sørensen, J.L. Fusarin C acts like an estrogenic agonist and stimulates breast cancer cells in vitro. Toxicol. Lett. 2011, 205, 116–121. [CrossRef] [PubMed]
120. Khosrokhavar, R.; Rahimifard, N.; Shoeibi, S.; Hamedani, M.P.; Hosseini, M.-J. Effects of zearalenone and α-Zearalenol in comparison with Raloxifene on T47D cells. Toxicol. Mech. Methods 2009, 19, 246–250. [CrossRef] [PubMed]
121. Parveen, M.; Zhu, Y.; Kiyama, R. Expression profiling of the genes responding to zearalenone and its analogues using estrogen-responsive genes. FEBS Lett. 2009, 583, 2377–2384. [CrossRef] [PubMed]
122. Belli, P.; Bellaton, C.; Durand, J.; Balleydier, S.; Milhau, N.; Mure, M.; Mornex, J.-F.; Benahmed, M.; Le Jan, C. Fetal and neonatal exposure to the mycotoxin zearalenone induces phenotypic alterations in adult rat mammary gland. Food Chem. Toxicol. 2010, 48, 2818–2826. [CrossRef] [PubMed]
123. Hsieh, C.-Y.; Santell, R.C.; Haslam, S.Z.; Helferich, W.G. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 1998, 58, 3833–3838. [PubMed]
124. Wang, T.T. Y.; Sathyamoorthy, N.; Phang, J.M. Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 1996, 17, 271–275. [CrossRef] [PubMed]
125. Rahman, H.P.; Hofland, J.; Foster, P.A. In touch with your feminine side: How oestrogen metabolism impacts prostate cancer. Endocr. Relat. Cancer 2016, 23, R249–R266. [CrossRef] [PubMed]
126. Majid, S.; Dar, A.A.; Ahmad, A.E.; Hirata, H.; Kawakami, K.; Shahryari, V.; Saini, S.; Tanaka, Y.; Dahiya, A.V.; Khatri, G.; et al. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis 2009, 30, 662–670. [CrossRef] [PubMed]
127. Vardi, A.; Bosviel, R.; Rabiau, N.; Adjakly, M.; Satih, S.; Dechelotte, P.; Boiteux, J.-P.; Fontana, L.; Bignon, Y.-J.; Guy, L.; et al. Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells. In Vivo 2010, 24, 393–400. [PubMed]
128. Lim, W.; Jeong, W.; Song, G. Coumestrol suppresses proliferation of ES2 human epithelial ovarian cancer cells. J. Endocrinol. 2016, 228, 149–160. [CrossRef] [PubMed]
129. Leclercq, G.; Jacquot, Y. Interactions of isoflavones and other plant derived estrogens with estrogen receptors for prevention and treatment of breast cancer-considerations concerning related efficacy and safety. J. Steroid Biochem. Mol. Biol. 2014, 139, 237–244. [CrossRef] [PubMed]
130. Li, Z.; Zhang, Y.; Hedman, A.C.; Ames, J.B.; Sacks, D.B. Calmodulin lobes facilitate dimerization and activation of estrogen receptor-α. J. Biol. Chem. 2017, 292, 4614–4622. [CrossRef] [PubMed]
131. Li, F.; Ye, L.; Lin, S.; Leung, L.K. Dietary flavones and flavonones display differential effects on aromatase (CYP19) transcription in the breast cancer cells MCF-7. Mol. Cell. Endocrinol. 2011, 344, 51–58. [CrossRef] [PubMed]
132. Nakamura, K.; Yang, J.-H.; Sato, E.; Miura, N.; Wu, Y.-X. Effects of hydroxy groups in the A-ring on the anti-proteasome activity of flavone. Biol. Pharm. Bull. 2015, 38, 935–940. [CrossRef] [PubMed]
133. Marcotte, R.; Sayad, A.; Brown, K.R.; Sanchez-Garcia, F.; Reimand, J.; Haider, M.; Virtanen, C.; Bradner, J.E.; Bader, G.D.; Mills, G.B.; et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell 2016, 164, 293–309. [CrossRef] [PubMed]
134. Singh, V.; Sharma, V.; Verma, V.; Pandey, D.; Yadav, S.K.; Maikhuri, J.P.; Gupta, G. Apigenin manipulates the ubiquitin–proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells. Eur. J. Nutr. 2015, 54, 1255–1267. [CrossRef] [PubMed]
135. Lecomte, S.; Lelong, M.; Bourgine, G.; Efstathiou, T.; Saligaut, C.; Pakdel, F. Assessment of the potential activity of major dietary compounds as selective estrogen receptor modulators in two distinct cell models for proliferation and differentiation. Toxicol. Appl. Pharmacol. 2017, 325, 61–70. [CrossRef] [PubMed]
136. Prossnitz, E.R.; Barton, M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat. Rev. Endocrinol. 2011, 7, 715–726. [CrossRef] [PubMed]
137. Chan, Q.K.Y.; Lam, H.-M.; Ng, C.-F.; Lee, A.Y.Y.; Chan, E.S.Y.; Ng, H.-K.; Ho, S.-M.; Lau, K.-M. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ. 2010, 17, 1511–1523. [CrossRef] [PubMed]